An increased HT‐22 apoptosis rate was observed 24 h post‐STZ induction, which improved following Laduviglusib intervention (Figure 2G), suggesting that GSK‐3β inhibition could mitigate HT‐22 apoptosis, thereby potentially ameliorating AD symptoms. The gene discussed is GSK3B; the disease is Alzheimer disease.